$RVMDRevolution Medicines, Inc.BATS:RVMDBlackLine_StrategiesRVMD Review — Opportunity vs. Cost Revolution Medicines represents an important advancement in cancer treatment, and the potential medical impact should not be overlooked. From an investment perspective, however, innovation does not automatically equal long-term profitability. With RASOnque reportedly priced around $39,800 per month, affordability and insurance reimbursement become major factors. In an economy where healthcare costs and insurance premiums are already elevated, widespread access could become a challenge even if the treatment is highly effective. On the other hand, approximately 55,000 new metastatic pancreatic cancer cases are estimated annually in the U.S. That creates a meaningful recurring addressable market and could support long-term revenue if adoption, insurance coverage, and clinical results remain strong. My view on RVMD: ⚡ Strong medical advancement ⚡ Significant unmet demand ⚡ Potential recurring patient market ⚠️ Very high treatment cost ⚠️ Insurance/reimbursement risk ⚠️ Valuation still has to match actual revenue growth The opportunity is real, but the long-term investment case will depend on how effectively RVMD converts medical success into accessible, sustainable commercial demand. Educational analysis only — not financial advice.